Who are Hepatitis A (control)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hepatitis A vaccine, Healive® Lot 3, Hepatitis A Virus, HAV vaccine, Havrix (HAV), Havrix+Healive.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hepatitis-a-control.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hepatitis A (control) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hepatitis A (control) (Hepatitis A (control)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: inactivated viral vaccine. Area: Immunology / Infectious Disease.

marketed inactivated viral vaccine Hepatitis A virus surface antigens Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Hepatitis A (control) (Hepatitis A (control)) — International Vaccine Institute. This inactivated hepatitis A vaccine stimulates the immune system to produce antibodies against hepatitis A virus, providing protective immunity against infection.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Hepatitis A (control) TARGET	Hepatitis A (control)	International Vaccine Institute	marketed	inactivated viral vaccine	Hepatitis A virus surface antigens
Hepatitis A vaccine	Hepatitis A vaccine	MacroGenics	marketed	inactivated viral vaccine	Hepatitis A virus surface antigens
Healive® Lot 3	Healive® Lot 3	Sinovac Biotech Co., Ltd	marketed	Inactivated viral vaccine	Hepatitis A virus surface antigens
Hepatitis A Virus	Hepatitis A Virus	Novartis	marketed	Inactivated viral vaccine	Hepatitis A Virus surface antigens
HAV vaccine	HAV vaccine	International Agency for Research on Cancer	phase 3	Inactivated viral vaccine	Hepatitis A virus surface antigens
Havrix (HAV)	Havrix (HAV)	Pfizer	marketed	Inactivated viral vaccine	Hepatitis A virus antigen
Havrix+Healive	Havrix+Healive	Sinovac Biotech Co., Ltd	marketed	Combination inactivated viral vaccine	Hepatitis A virus antigen; Hepatitis B surface antigen (HBsAg)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (inactivated viral vaccine class)

Sinovac Biotech Co., Ltd · 5 drugs in this class
Sinovac Research and Development Co., Ltd. · 2 drugs in this class
Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
Federal University of Espirito Santo · 1 drug in this class
International Vaccine Institute · 1 drug in this class
MacroGenics · 1 drug in this class
Shandong Province Centers for Disease Control and Prevention · 1 drug in this class
Beijing Chaoyang District Centre for Disease Control and Prevention · 1 drug in this class
Zhejiang Provincial Center for Disease Control and Prevention · 1 drug in this class
Centers for Disease Control and Prevention · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hepatitis A (control) — Competitive Intelligence Brief. https://druglandscape.com/ci/hepatitis-a-control. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing